Our data suggest that both compounds can reduce the secretion of IL-6 after LPS stimulation, corroborating results of previous studies that showed the involvement of the IL-6/JAK/STAT3 signaling pathway in the progression of prostate cancer and that the inhibition of p-STAT3 is essential to reduce IL-6 release. The gene discussed is IL6; the disease is prostate cancer.